志贺桿菌检测套组市场 - 全球产业规模、份额、趋势、机会及预测（按检测类型、技术、最终用户、地区和竞争格局划分，2021-2031年）

全球志贺氏菌检测套组市场预计将从 2025 年的 1.7886 亿美元成长到 2031 年的 2.7008 亿美元，复合年增长率为 7.11%。

这些试剂盒是用于识别临床粪便检体中志贺氏菌抗原或遗传物质的重要诊断设备，利用侧向层析免疫检测和分子聚合酵素链锁反应等技术来确诊志志贺氏桿菌感染。市场成长的主要驱动力是全球食源性疾病发生率的不断上升，以及检测抗药性菌株的迫切需求，而准确的药敏试验对于指导有效治疗至关重要。英国健康与安全执行局的数据显示，预计到2023年，广泛抗药性志志贺桿菌菌病例将激增53%，凸显了快速、精准的诊断能力对于应对这一日益严重的公共卫生威胁的紧迫性。

儘管成长要素强劲，但先进分子诊断平台的高昂实施成本仍是该市场面临的一大障碍。这个经济门槛限制了资源匮乏地区（通常是痢疾高发地区）采用现代检测方案。此外，这些发展中地区检查室基础设施不足，也使得全面检测通讯协定的实施更加复杂，阻碍了该市场在全球范围内的推广和扩张。

市场驱动因素

多重抗药性志志贺桿菌菌株的日益增多是全球志贺桿菌检测套组市场的主要驱动因素。对阿奇霉素和Ciprofloxacin等第一线标准抗生素的抗药性不断增强，使得临床检查室迫切需要部署先进的诊断解决方案，以识别病原体及其特定的抗药性标记，从而确保有效治疗。近期关于危险突变菌株传播的监测数据凸显了这种迫切性。 2024年8月，加州公共卫生部报告称，2024年1月至5月期间，该州检测到的志贺桿菌分离株中，被鑑定为广泛抗药性（XDR）菌株的比例上升至12%，较上年的6.8%显着增加。因此，医疗机构正在优先部署能够支援准确临床决策的检测套组，以应对这些复杂且棘手的感染疾病。

分子诊断技术的进步，使得透过综合征检测组合实现快速、高通量检测成为可能，进一步推动了市场成长。从传统的培养方法转向多重聚合酵素链锁反应(PCR) 系统，可以同时鑑定志贺氏菌和其他肠道病原体，显着缩短检测结果的周转时间，并增强疫情应对能力。对快速诊断的需求在近期的行业趋势中显而易见。 2024 年 3 月，生物梅里埃公司 (bioMérieux) 报告称，其包含胃肠道检测在内的非呼吸道 BIOFIRE 检测组合在 2023 年第四季度的销售额增长了 20%。美国疾病管制与预防中心 (CDC) 估计，到 2024 年，仅在美国每年就会发生约 45 万志贺氏桿菌感染，这使得这些先进的诊断工具对于控制巨大的疾病负担至关重要。

市场挑战

实施先进分子诊断平台的高成本是全球志贺氏菌检测套组市场成长的一大障碍。这一经济障碍严重限制了资源匮乏经济体（疾病负担最重的地区）采用现代检测方案。这些发展中地区的医疗预算往往捉襟见肘，导致医疗机构无力购买和维护进行精准药敏分析所需的昂贵设备。因此，该市场面临结构性扩张限制，未能充分满足临床需求最迫切地区的市场需求。

这些地区检测基础设施的匮乏进一步加剧了必要检测通讯协定实施的困难。无法建立可靠的诊断能力阻碍了复杂抗药性菌株的识别，最终限制了市场潜力。近期抗药性的趋势凸显了这个问题的严重性，而这需要先进的检测技术。根据加州公共卫生部统计，2024年1月至5月，广泛抗药性的志志贺桿菌分离株的盛行率上升至12%，比前一年增加了78%。抗药性的激增凸显了对先进诊断技术的迫切需求，然而，这些工具的高昂成本仍然阻碍着市场渗透和整个产业的成长。

市场趋势

多综合征胃肠道病原体检测组合的广泛应用正在改变市场格局，解决了临床上区分志志贺氏桿菌感染与其他症状相似的肠道病原体感染疾病的难题。与传统的单一标靶检测不同，这些综合检测组合能够同时检测多种细菌、病毒和寄生虫，从而降低诊断的不确定性，并在复杂的临床情况下优化患者管理。这种提高诊断准确性的趋势在近期推出的产品中也得到了体现。例如，凯杰公司宣布将于2024年6月在美国推出QIAstat-Dx胃肠道病原体检测组合2，该组合可在约一小时内快速识别多达16种常见的胃肠道病原体。

同时，随着医疗机构寻求简化高通量诊断流程并缓解长期存在的人员短缺问题，自动化即时PCR检测在临床检查室中的应用正在加速推进。医疗机构越来越多地采用全自动分子平台，这些平台能够最大限度地减少人工操作并提高检测通量，从而实现常规胃肠道检体的高效处理，突破了人工方法的局限性。这种向自动化营运的转变显着推动了商业性应用，Seegene公司报告称，其胃肠道诊断产品在2024年5月的销售额同比增长了36%。这项业绩主要得益于成功拓展了向先进自动化解决方案转型的新客户。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球志志贺桿菌检测套组市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依检测类型（横向流动化验、酵素免疫分析法(ELISA)、聚合酵素链锁反应(PCR) 检测、其他）
  • 依技术分类（传统诊断检验、核酸检验、其他）
  • 依最终使用者（医院、诊断检查室、研究机构等）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美志志贺桿菌检测套组市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲志贺桿菌检测套组市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区志贺桿菌检测套组市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲志贺桿菌检测套组市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美志志贺桿菌检测套组市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球志贺桿菌检测套组市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Meridian Bioscience, Inc.
• QIAGEN NV
• Diasorin SpA
• Bio-Rad Laboratories Inc.
• BioMerieux SA
• Hygiena LLC
• Molbio Diagnostics Pvt. Ltd.
• Fujirebio Diagnostics, Inc.
• CTK Biotech, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Shigella Test Kit Market is projected to expand from USD 178.86 Million in 2025 to USD 270.08 Million by 2031, reflecting a CAGR of 7.11%. These kits serve as essential diagnostic instruments for identifying Shigella antigens or genetic material in clinical stool specimens, utilizing technologies such as lateral flow immunoassays and molecular polymerase chain reaction to confirm shigellosis infections. The market is primarily propelled by the increasing global incidence of foodborne diseases and the critical requirement to detect antimicrobial-resistant strains, which necessitate accurate sensitivity profiling to direct effective treatment. Data from the UK Health Security Agency indicates that extensively antibiotic-resistant Shigella cases surged by 53 percent in 2023, highlighting the urgent need for rapid and precise diagnostic capabilities to address this growing public health threat.

Despite these strong growth factors, the market encounters a significant obstacle regarding the high implementation expenses of advanced molecular diagnostic platforms. This financial hurdle restricts the adoption of modern testing solutions in resource-limited settings, which are often the regions where shigellosis is most endemic. Furthermore, the lack of adequate laboratory infrastructure in these developing areas complicates the application of comprehensive testing protocols, thereby hindering the market's global reach and expansion.

Market Driver

The escalating burden of multidrug-resistant Shigella strains acts as a primary catalyst for the Global Shigella Test Kit Market. As resistance to standard first-line antibiotics like azithromycin and ciprofloxacin intensifies, clinical laboratories are urged to implement advanced diagnostic solutions capable of identifying both the pathogen and specific resistance markers to ensure effective therapy. This urgency is emphasized by recent surveillance data on the spread of dangerous variants; the California Department of Public Health reported in August 2024 that the percentage of Shigella isolates identified as extensively drug-resistant (XDR) in California increased to 12% between January and May 2024, a significant rise from 6.8% the previous year. Consequently, healthcare providers are prioritizing test kits that support accurate clinical decision-making to manage these complex, hard-to-treat infections.

Technological progress in molecular diagnostics further drives market growth by facilitating rapid, high-throughput detection via syndromic testing panels. The transition from traditional culture methods to multiplex polymerase chain reaction (PCR) systems enables the simultaneous identification of Shigella and other enteric pathogens, significantly reducing turnaround times and enhancing outbreak response. This demand for rapid diagnostics is evident in recent industry performance; BioMerieux reported in March 2024 that sales for its BIOFIRE non-respiratory panels, which include gastrointestinal testing, grew by 20% in the fourth quarter of 2023. These advanced tools are vital for managing the substantial disease burden, as the Centers for Disease Control and Prevention estimated in 2024 that approximately 450,000 Shigella infections occur annually in the United States alone.

Market Challenge

The substantial implementation costs associated with advanced molecular diagnostic platforms present a major impediment to the growth of the Global Shigella Test Kit Market. This financial barrier severely limits the adoption of modern testing solutions in resource-limited economies, which represent the regions with the highest endemic burden of the disease. Since healthcare budgets in these developing areas are often restricted, facilities are unable to procure or maintain the expensive instrumentation required for precise sensitivity profiling. Consequently, the market faces a structural ceiling on its expansion, remaining unable to capitalize on the demand in geographies where the clinical need is most acute.

The insufficiency of laboratory infrastructure in these regions further complicates the deployment of necessary testing protocols. This inability to establish robust diagnostic frameworks prevents the identification of complex resistant strains, thereby limiting the market's reach. The severity of this issue is underscored by recent resistance trends that require such advanced detection; according to the California Department of Public Health, in 2024, the prevalence of extensively drug-resistant Shigella isolates rose to 12 percent between January and May, reflecting a 78 percent increase compared to the previous year. This escalation in resistance highlights the critical need for advanced diagnostics, yet the prohibitive costs associated with these tools continue to hamper their market penetration and overall industry growth.

Market Trends

The widespread adoption of multiplex syndromic gastrointestinal panels is transforming the market by addressing the clinical difficulty of distinguishing shigellosis from infections caused by other enteric pathogens with identical symptom profiles. Unlike traditional single-target tests, these comprehensive panels allow for the simultaneous detection of a wide array of bacteria, viruses, and parasites, thereby reducing diagnostic uncertainty and optimizing patient management in complex clinical scenarios. This trend toward broader diagnostic granularity is illustrated by recent product launches; for instance, Qiagen announced in June 2024 the U.S. launch of its QIAstat-Dx Gastrointestinal Panel 2, which enables the rapid identification of up to 16 common gastrointestinal pathogens in approximately one hour.

Simultaneously, the integration of automated real-time PCR assays in clinical laboratories is accelerating as facilities seek to streamline high-volume diagnostic workflows and alleviate chronic staff shortages. Healthcare providers are increasingly adopting fully automated molecular platforms that minimize manual handling and enhance throughput, allowing for the efficient processing of routine gastrointestinal samples beyond the capacity of manual methods. This operational shift toward automation is driving significant commercial uptake; Seegene Inc. reported in May 2024 that sales for its gastrointestinal diagnostic products grew by 36 percent year-over-year, a performance attributed to the successful acquisition of new customers transitioning to advanced automated solutions.

Key Market Players

• Thermo Fisher Scientific Inc.
• Meridian Bioscience, Inc.
• QIAGEN N.V.
• Diasorin S.p.A.
• Bio-Rad Laboratories Inc.
• BioMerieux SA
• Hygiena LLC
• Molbio Diagnostics Pvt. Ltd.
• Fujirebio Diagnostics, Inc.
• CTK Biotech, Inc.

Report Scope

In this report, the Global Shigella Test Kit Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Shigella Test Kit Market, By Test Type

• Lateral flow assays
• Enzyme-linked immunosorbent assay (ELISA)
• Polymerase chain reaction (PCR) assay
• Others

Shigella Test Kit Market, By Technology

• Conventional diagnostic tests
• Nucleic acid-based tests
• Others

Shigella Test Kit Market, By End User

• Hospitals
• Diagnostic laboratories
• Research institutes
• Others

Shigella Test Kit Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Shigella Test Kit Market.

Available Customizations:

Global Shigella Test Kit Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Shigella Test Kit Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Lateral flow assays, Enzyme-linked immunosorbent assay (ELISA), Polymerase chain reaction (PCR) assay, Others)
  • 5.2.2. By Technology (Conventional diagnostic tests, Nucleic acid-based tests, Others)
  • 5.2.3. By End User (Hospitals, Diagnostic laboratories, Research institutes, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Shigella Test Kit Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Technology
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Shigella Test Kit Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Shigella Test Kit Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Shigella Test Kit Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End User

7. Europe Shigella Test Kit Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Technology
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Shigella Test Kit Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End User
  • 7.3.2. France Shigella Test Kit Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Shigella Test Kit Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Shigella Test Kit Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Shigella Test Kit Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End User

8. Asia Pacific Shigella Test Kit Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Technology
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Shigella Test Kit Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End User
  • 8.3.2. India Shigella Test Kit Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Shigella Test Kit Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Shigella Test Kit Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Shigella Test Kit Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By End User

9. Middle East & Africa Shigella Test Kit Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Technology
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Shigella Test Kit Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Shigella Test Kit Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Shigella Test Kit Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End User

10. South America Shigella Test Kit Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Technology
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Shigella Test Kit Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Shigella Test Kit Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Shigella Test Kit Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Shigella Test Kit Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Meridian Bioscience, Inc.
• 15.3. QIAGEN N.V.
• 15.4. Diasorin S.p.A.
• 15.5. Bio-Rad Laboratories Inc.
• 15.6. BioMerieux SA
• 15.7. Hygiena LLC
• 15.8. Molbio Diagnostics Pvt. Ltd.
• 15.9. Fujirebio Diagnostics, Inc.
• 15.10. CTK Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer